| Value | ₹49.00 Cr |
|---|
BSE filing, BSE: 544304. Summary written from the filing by ALFA Finder's alert engine.
Jungle Camps India Ltd: key numbers
- Share price
- ₹41.92
- Market cap
- ₹64.97 Cr
- Revenue (annual)
- ₹23.28 Cr
- Net profit (annual)
- ₹4.22 Cr
- P/E (TTM)
- 15.4×Sector 43.7×
- Promoter holding
- 69.63%+0.00% QoQ
- FII holding
- 1.57%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Jungle Camps India Ltd
All →Jungle Camps India Other Announcement
Jungle Camps India filed a revised shareholding pattern for the quarter ended 30 September 2026. The revision corrects a clerical omission in the 1% shareholder disclosure.
Jungle Camps India Other Announcement
Jungle Camps India Ltd has filed its quarterly shareholding pattern report for the period ended September 30, 2026, as mandated by SEBI regulations.
Jungle Camps India Annual General Meeting
Jungle Camps India Ltd held its 24th Annual General Meeting on 26th September 2026. The meeting covered adoption of financial statements and re-appointment of a director.
Jungle Camps India Annual Report
Jungle Camps India Ltd has submitted its Annual Report for the financial year 2025-26, including the Notice for its 24th Annual General Meeting.
Jungle Camps India Annual General Meeting
Jungle Camps India Ltd has submitted the Notice for its 24th Annual General Meeting, scheduled for September 26, 2026, along with the Annual Report for FY 2025-26.
Jungle Camps India Management Change
Mr. Shailendra Singh resigned as Independent Director of Jungle Camps India Limited effective August 27, 2026. The resignation follows his appointment as Chairperson of MP RERA.
Other fund raise announcements
All →Rite Zone Chemcon India Fund Raise of ₹6.58 Cr
Rite Zone Chemcon India announced a preferential issue of 27,69,730 equity shares to 11 investors at Rs.24 each, raising about Rs.6.58 Crore. The approval awaits a shareholder vote on 23 November 2026.
- Value
- ₹6.58 Cr
Sudarshan Pharma Industries Fund Raise of ₹72 Cr
Sudarshan Pharma's board approved up to Rs. 72 Crore of preferential convertible warrants for promoters Hemal and Sachin Mehta. Shareholder approval will be sought at an EGM.
- Value
- ₹72.00 Cr
Flywings Simulator Training Centre Fund Raise of ₹68.2 Cr
Flywings Simulator's board approved Rs. 68.20 Crore fully convertible warrants on a preferential basis. Promoter Rupal Mandavia is allotted Rs. 25 Crore, subject to shareholder approval.
- Value
- ₹68.20 Cr
Kanel Industries Fund Raise of ₹16.99 Cr
Kanel Industries' board approved a rights issue of 42.52 lakh equity shares at Rs.39.95 each. The issue aggregates about Rs.16.99 Crore, with record date 13 November 2026.
- Value
- ₹16.99 Cr
- Execution
- Rights issue opens 23 November 2026 and closes 30 November 2026
Sudarshan Pharma Industries Fund Raise
Board approved issuing up to 72 Crore warrants to promoters on a preferential basis. Pricing per Reg 164 is pending, with no fixed rupee value stated.
GAIL (India) Fund Raise
GAIL Board approved in principle the IPO of subsidiary GAIL Gas Limited on Indian exchanges. GAIL will dilute its GGL equity up to 25%.